Paper30119081
Bevacizumab and Glioblastoma: Past, Present, and Future Directions.
Kim MM and 2 others. Cancer J, 2018. Cited by 94 papers, by iCite.
Cite this record
ConductScience Library. Bevacizumab and Glioblastoma: Past, Present, and Future Directions. Papers, record 30119081. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30119081
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Angiogenesis Inhibitors | Major topic |
| Antineoplastic Agents, Immunological | Major topic |
| Bevacizumab | Major topic |
| Glioblastoma | Major topic |
| Animals | |
| Antineoplastic Combined Chemotherapy Protocols | |
| Biomarkers, Tumor | |
| Clinical Trials as Topic | |
| Humans | |
| Immunomodulation | |
| Molecular Targeted Therapy | |
| Recurrence | |
| Treatment Outcome | |
| Vascular Endothelial Growth Factor A |
Source PubMed
Cited by62
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 94 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42017986 | Interactions and communications in the glioblastoma microenvironment: potential targets for chemo-/radiotherapy. | Strahlenther Onkol | 2026 | https://conductscience.org/library/papers/42017986 | PubMed |
| 41758210 | KDM6B promotes VEGFA expression and vasculogenic mimicry in glioblastoma cells under hypoxia conditions. | Exp Brain Res | 2026 | https://conductscience.org/library/papers/41758210 | PubMed |
| 41495049 | Intrathecal CRISPR-edited allogeneic IL-13Rα2 CAR T Cells for recurrent high-grade Glioma: preclinical characterization and phase I trial. | Nat Commun | 2026 | https://conductscience.org/library/papers/41495049 | PubMed |
| 40917884 | Comparative efficacy and safety of therapeutic strategies for EGFRvIII positive recurrent glioblastoma. | iScience | 2025 | https://conductscience.org/library/papers/40917884 | PubMed |
| 40701845 | Fimepinostat is a dual inhibitor of tumor and angiogenesis in glioblastoma and synergizes with temozolomide through suppressing MYC. | Korean J Physiol Pharmacol | 2025 | https://conductscience.org/library/papers/40701845 | PubMed |
| 40699793 | Could Fingolimod Combined with Bevacizumab Be a New Hope in Glioblastoma Treatment? | Curr Issues Mol Biol | 2025 | https://conductscience.org/library/papers/40699793 | PubMed |
| 39893170 | Network analyses of brain tumor multiomic data reveal pharmacological opportunities to alter cell state transitions. | NPJ Syst Biol Appl | 2025 | https://conductscience.org/library/papers/39893170 | PubMed |
| 39575164 | Dose and Efficacy of Bevacizumab in Recurrent High-Grade Gliomas: A Retrospective Study. | Cancer Manag Res | 2024 | https://conductscience.org/library/papers/39575164 | PubMed |
| 39484048 | Tumor treating induced fields: a new treatment option for patients with glioblastoma. | Front Neurol | 2024 | https://conductscience.org/library/papers/39484048 | PubMed |
| 39308833 | Comparative Volumetric Analyses Following Bevacizumab Therapy for a Patient With Concomitant Glioblastoma, Meningioma, and Dural Arteriovenous Fistula: A Case Report and Review of Literature. | Cureus | 2024 | https://conductscience.org/library/papers/39308833 | PubMed |
| 39061228 | Bevacizumab-Based Therapies in Malignant Tumors-Real-World Data on Effectiveness, Safety, and Cost. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39061228 | PubMed |
| 38848215 | Lineage specification in glioblastoma is regulated by METTL7B. | Cell Rep | 2024 | https://conductscience.org/library/papers/38848215 | PubMed |
| 38803685 | Expression of the apelin receptor, a novel potential therapeutic target, and its endogenous ligands in diverse stem cell populations in human glioblastoma. | Front Neurosci | 2024 | https://conductscience.org/library/papers/38803685 | PubMed |
| 38716237 | Direct antitumor activity of bevacizumab: an overlooked mechanism? | Front Pharmacol | 2024 | https://conductscience.org/library/papers/38716237 | PubMed |
| 38484377 | [Systemic treatment of adult gliomas: a narrative review]. | Magy Onkol | 2024 | https://conductscience.org/library/papers/38484377 | PubMed |
| 38258110 | Targeted Glioma Therapy-Clinical Trials and Future Directions. | Pharmaceutics | 2024 | https://conductscience.org/library/papers/38258110 | PubMed |
| 37762559 | Understanding Glioblastoma Signaling, Heterogeneity, Invasiveness, and Drug Delivery Barriers. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37762559 | PubMed |
| 37686584 | The Development of Immunotherapy for the Treatment of Recurrent Glioblastoma. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37686584 | PubMed |
| 37548850 | First in-human intrathecal delivery of bevacizumab for leptomeningeal spread from recurrent glioblastoma: rationale for a dose escalation trial. | J Neurooncol | 2023 | https://conductscience.org/library/papers/37548850 | PubMed |
| 37540556 | Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma. | Clin Cancer Res | 2023 | https://conductscience.org/library/papers/37540556 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30119081
GET https://conductscience.org/api/papers/v1/30119081/cited_by?page=2